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There is an urgent need to develop better therapeutics for autoimmune and autoinﬂammatory diseases, of which musculoskeletal
disorders such as rheumatoid arthritis are particularly prevalent and debilitating. Helminth parasites are accomplished masters at
modifying their hosts’ immune activity, and so attention has focused on rodent-helminth model systems to uncover the workings
of the mammalianimmune response to metazoan parasites, with the hope of revealing molecules and/or mechanisms that can be
translated into better treatments forhumanautoimmuneand idiopathicdisorders.Substantialproof-of-principaldata supporting
the concept that infection with helminth parasites can reduce the severity of concomitant disease has been amassed from models
of mucosal inﬂammation. Indeed, infection with helminth parasites has been tried as a therapy in inﬂammatory bowel disease,
and there are case reports relating to other conditions (e.g., autism); however, the impact of infection with parasitic helminths on
musculoskeletal diseases has not been extensively studied. Here, we present the view that such a strategy should be applied to the
amelioration of joint inﬂammationand review the literature that supports this contention.
1.Introduction
Infectionwithhelminthparasitesresultsinaconservedseries
of immune events that are orchestrated and dominated by
T helper cell type 2 (Th2) events [1]. Given the reciprocity
in immune regulation where, for example, Th2 cell-derived
mediators inhibit the activity of Th1 cells, the hypothesis
arises that individuals infected with helminth parasites
could be less susceptible to other inﬂammatory diseases.
By extrapolation, infection with helminth parasites could
be used to treat disease driven by Th1 cells. Many species
of parasitic helminths reside at mucosal surfaces, and it
has repeatedly been shown that infection with trematode,
cestode, or nematode parasites can reduce the severity of
colitis and airway inﬂammation in murine models [2]. The
impact of infection with helminths on organs outside the
parasite’slocationhasreceivedlessattention.Here,wereview
the eﬀect of infection with helminth parasites on joint
inﬂammation.
The last four decades have seen an alarming increase in
the prevalence of autoimmune diseases such as inﬂamma-
tory bowel disease (IBD), diabetes, multiple sclerosis, and
rheumatoid arthritis (RA) in Western societies. Rheumatoid
arthritis is a painful and debilitating disease that aﬀects ∼1%
of the North American population [3]. The socioeconomic
burden of this disease is substantial; in 2003 arthritis and
other rheumatic conditions cost the United States $127.8
billion per year, an amount equivalent to 1.2% of the GDP
and tantamount to a small, chronic recession [4].
Current therapies for RA include nonsteroidal anti-
inﬂammatory drugs (NSAIDs), glucocorticoids (GCs), and
disease-modifying antirheumatic drugs (DMARDs).As their
name implies NSAIDs inhibit inﬂammation, although their
mild-to-moderate eﬀects do not fully alleviate the symp-
toms of RA. Moreover, these drugs do not inhibit the
progression of arthritic disease; thus joint damage persists.
Adverse reactions in the gastrointestinal tract (GIT), kidney,
and central nervous systems are frequently reported with2 Journal of Parasitology Research
the use of NSAIDs [5]. Glucocorticoids possess potent
immunosuppressive and anti-inﬂammatory properties [6],
but their use comes with considerable long-term risks:
for example, GCs decrease calcium absorption and impair
bone formation, leading to a signiﬁcant decline in bone
mineral density within the ﬁrst 6–12 months of therapy [6].
Additional side eﬀects of sustained GC use include weight
gain, redistribution of adipose tissue, and increased risk
of developing diabetes mellitus, peptic ulcers, pancreatitis,
cataracts, and glaucoma [6]. While DMARDs have been
successful in slowing the progression of bone and cartilage
erosion, these drugs (e.g., methotrexate (MTX)), even at
low doses, can generate a variety of toxic side eﬀects [7].
Toxic eﬀects of MTX have been observed in the liver and
GIT, mucous and skin membranes, and the respiratory and
hematopoietic systems [7].
Despite many pharmacological advances, the limited
eﬀectiveness and adverse side eﬀects of current therapies for
arthritic diseases highlight the urgent need for alternative
treatment(s), which can only be generated through a better
understanding of the mediators and mechanisms that gen-
erate pain and inﬂammation in the joint [8]. While animal
models do not fully replicate human RA, they are invaluable
tools for elucidating immunopathological processes that can
cause arthritis. For example, the inhibition of arthritic dis-
ease in mice by neutralizing the proinﬂammatory cytokine,
tumor necrosis factor (TNF)-α, has led to the introduction
of anti-TNFα therapy in clinical practice [9].
2.Animal ModelsofJointInﬂammation
Numerous studies suggest that RA is more accurately
classiﬁed as a syndrome rather than one speciﬁc disease,
as evidenced by the complex pathophysiological pathways
involved. There exists a wide diversity of models of joint
inﬂammationthatemployrabbits,guineapigs,andprimates,
although rodents are, by far, the most commonly used
(Table 1).The induction ofarthritis in these modelstypically
employs the administration of an adjuvant ± an antigen,
with the antigen immunization generating immunological
memory. The use of transgenic mouse technology and the
development of knock-out strains of mice have provided the
opportunity to examine the “spontaneous” development of
arthritis, and the genes and proteins that contribute to joint
inﬂammation.
The most commonly used model of arthritis is the type
II collagen (Col II) model. Collagen is a key component
of cartilage, and immunologic hypersensitivity to Col II
results in joint inﬂammation. In this model, animals are
immunized with type II collagen (from the same or a
diﬀerent species) that is emulsiﬁed in Freund’s adjuvant.
This provokes a multijoint inﬂammation characterized by
synovitis, inﬂammatory cell inﬁltrate, pannus formation,
bone and cartilage erosion, and ﬁbrosis: features that more
closely resemble human RA than those observed with
adjuvant only-induced arthritis [26]. The source of collagen
used for immunization aﬀects the character of the disease:
heterologous (from a diﬀerent species) Col II elicits an
acute and severely erosive polyarthritis 2-3 weeks after
immunization, while homologous Col II evokes a severe and
more chronic form of arthritis [24].
Arthritis is commonly induced through the use of
Freund’s adjuvant (mineral oil) with (Freund’s Complete
adjuvant; CFA) or without (Freund’s incomplete adjuvant;
IFA) the addition of an inactivated bacterium (frequently
Mycobacterium tuberculosis). CFA is eﬀective in stimulat-
ing cell-mediated immunity, leading to the production of
antibodies. Depending on the route of administration, a
systemic or local arthritic eﬀect can be induced. Intra-
articular injection of CFA results in a monoarthritis which
spares the other joints, and while not fully recapitulating RA
this oﬀers the advantage of a localised inﬂammation with
reducedsystemic involvementandallowsforpainassessment
studies in which the contralateral, noninjected joint acts as
an internal control. The CFA model is often used for testing
potential anti-inﬂammatory or antinociceptive therapeutic
agents.
The most recent addition to the panoply of models of
arthritis has been the useof transgenic animals engineered to
either overexpress or to lack a particular gene either globally
or in a speciﬁc tissue. For example, overexpression of TNF-α
resultedin thespontaneousdevelopmentofachronic erosive
arthritis in 100% of the animals, with lesions similar to RA
[27].
Before considering the impact of infection with
helminths on joint inﬂammation, we must ﬁrst brieﬂy
outline the immune response to infection with these
metazoan parasites, as this is important to subsequent
analyses of how “bystander’ diseases can be modiﬁed by the
parasite or the host response to the infection [1].
3.Mammalian Immune Response to
Helminth Parasites
Although the precise nature of the host immune response
varies considerably between species, a Th2 phenotype is
a conserved response to helminth infection in mice and
humans and is marked by the production of signiﬁcant
amounts of interleukins (IL)-4, -5, -9, -10, and -13 [1,
28], and the more recently identiﬁed IL-21 and IL-33.
Mucosal mast cell hyperplasia, eosinophilia, IgE production,
and increased expression of goblet cells are immunologic
responses characteristic of infection with parasitic helminths
[29]. Basically, there exist two potential mechanisms by
which parasites can aﬀect host immunity in a manner that
would modify concomitant disease. First, products secreted
from the parasite could have immunomodulatory eﬀects;
that is, they exert the capacity to directly modulate host
immune functions. Second, the immune response generated
to combat the infection couldcounteract the immunopatho-
logical reactions that drive autoimmune diseases. A widely
recognized feature of helper T cells is that, in the presence
of Th2 eﬀector responses, Th1 responses are suppressed
and vice versa. Thus, Th2-type reactions evoked in response
to helminth infection would in theory have the ability
to suppress proinﬂammatory Th1 responses that generateJournal of Parasitology Research 3
Table 1: Summary of some of the most commonrodent models of musclo-skeletaldisease.
Principle Model Induction Immunologicalfeatures Reference
Cartilage complex
autoimmunity
Collagen-induced
arthritis (CIA)
Immunization with
homologous or
heterologous type II
collagen
(i) Increases in
anticollagen AB
(ii) Increases in
complement,
neutrophils,
macrophages,B cells,
and α/β TCR+/CD4+ T
cells
(iii) Increases in TNFα,
TGFβ2,I L - 1 ,I L - 6 ,I L - 1 7
and IFNγ,a n dI L - 1 2
(later phases)
[10–13]
Proteoglycan-induced
arthritis
IP injections in FCA at 0
and 1 weeks; IP
injections in FIA at week
4a n d7
(i) Increases in CD4+ T
cells and Th1-type
cytokines, particularly
IFNγ
[14]
K/BxN serum transfer IP injection of serum
from KRNxNOD strain
(i) Increases in GPI
antibodies, mast cells,
neutrophils, TNFα,a n d
IL-1
[15]
Infection Mycoplasma infection IV injection with M.
arthriticus
(i) Increases in Th1 in
susceptible mice
Increases in Th2 in
arthritis-resistant mice
(ii) Suppression of
T-lymphocyte
proliferation and IL-2
Increases in IL-4 and
IL-6
[16, 17]
Staphylococcus infection IV injection with S.
aureus
(i) Increases in TNFα,
TNFβ,I L - 1 β,a n dI L - 1 2 [18]
Bacterial fragment induced
Streptococcal cell wall
(SCW) IP/IA injection of SCW
(i) Increases in TNFα,
TNFβ,I L - 1 ,I L - 6 ,I F N β,
and IFNγ
(ii) Increases in CD4+ T
cells in chronic, not
acute arthritis
[19–21]
Mycobacterium in FCA IA injection
(i) Increases in
circulating neutrophils,
TNFα, IL-12p40, and
IL-17
[22, 23]
Adjuvantinduced
Avridine SC injection
(i) Activated
macrophages,CD4+ T
cells
[24]
Pristane
SC (rats) or IP (mice)
injection + booster 7
weeks later
(ii) Increases in TNFα,
IL-1β,a n dI L - 6 [25]
Oil induced FIA SC injection
(iii) Increases in
macrophages,
neutrophils, CD4+ T
cells, B cells, TNFα,a n d
IL-6
[24]
Genetic manipulation TNFα TNF transgenic strain;
spontaneous
(i) Increases in TNFα,
IL-6, and IL-1β [21]
(AB: antibodies; CFA: Freund’s complete adjuvant; FIA: Freund’s incomplete adjuvant; GPI: glucose-6 phosphate isomerase; IA: intra-articular; IFNγ:
interferon-gamma; IL: interleukin; IP: intraperitoneal; IV: intravenous; KXN: T-cell receptor transgene mouse strain; NOD: nonobese diabetic mouse strain;
RA: rheumatoid arthritis; SC: subcutaneous; TGFβ:t r a n s f o r m i n gg r o w t hf a c t o r - b e t a ;T N F α: tumour necrosis factor-alpha).4 Journal of Parasitology Research
immunopathology. Models that incorporate infection with
helminth parasites in conjunction with the expression of
autoimmune diseases are proving to be extremely useful in
elucidating immuno-regulatory pathways. Indeed, a picture
is emerging in which infection with helminth parasites leads
to a general dampening of host immunity or the creation
of an immuno-regulatory environment (dominated by IL-
10, transforming-growth factor (TGF-β), regulatory T cells,
and alternatively activated macrophages) that can explain
the seemingly paradoxical observation that the “helminth
therapy” may reduce Th2-dominated conditions such as
allergy and atopy [1, 2]. The goal of research with these
animal models is that characterization of the host-parasite
relationship will lead to the identiﬁcation of therapeutic
agents to control proinﬂammatory events.
3.1. Parasite-Derived Immunomodulatory Molecules. Virtu-
ally, all helminths studied to date express one or more
molecules that can modify the activity of their host’s
immune response; however, the majority of these are
poorly characterized [30, 31]. A notable exception is ES-
62, a glycoprotein derived from Acanthocheilonema vitea.
The numerous immuno-regulatory capacities of ES-62 are
attributed to the presence of phosphorylcholine [32]. Fea-
tures of ES-62-induced immune modulation include altered
B-cell and cytokine proliferation, a shift towards an anti-
inﬂammatory phenotype of antigen presenting cells, and
reduced mast cell degranulation. Mechanistically, the action
of ES-62 is in part attributed to its ability to downregulate
protein kinase C, a signalling enzyme that plays a role in
B cell proliferation and mast cell degranulation [33, 34].
In murine models, ES-62 induces a cytokine and antibody
shift characterized by increased levels of IL-10, reduced
levels of proinﬂammatory cytokines (IL-12, TNFα), and the
production of IgG1 molecules [34]. Thus, ES-62 does not
simply function as an immunosuppressant; rather it induces
active anti-inﬂammatory responses via Th2-driven events.
Administration of ES-62 can protect mice from collagen-
induced arthritis through its inhibition of the production
and activity of proinﬂammatory cytokines (e.g., IL-6, TNFα,
and IFNγ) and collagen-speciﬁc antibodies and evoking the
increased synthesis of IL-10 [35]. In terms of the relief
of the symptoms of arthritis, ES-62 treatment resulted in
reduced progression of knee swelling with the involvement
of fewer joints, and synovial hyperplasia, cellular inﬁltration,
and bone erosion were suppressed. In the presence of ES-
62, cultures from human RA synovial ﬂuid and membranes
expressed reduced levels of TNFα,I L - 6[ 35], and IFNγ [36],
while peripheral blood mononuclear cells from patients with
RA exhibited low IFNγ secretion following ES-62 challenge
[36].
Despitethemyriad ofpartiallypuriﬁedhelminth-derived
moleculesthat can suppress or redirect mammalian immune
responses, the promise of helminths as a source of anti-
inﬂammatory or immunomodulatory drugs has yet to
materialize[30,31].Onereasonforthishasbeentheinability
to isolate pure antigens/molecules from small amounts of
parasite tissue; however, we contend that this should not
deter the search for these molecules. Technological advances
in recent years (e.g., mass spectrometry) have enhanced
our ability to isolate, characterize, and purify molecules
from miniscule amounts of starting material. Additionally, a
wealth of simple bioassays is available to screen the potential
immunomodulatory properties of these molecules.
4.SuppressionofJoint Inﬂammationby
Helminth Parasites
Numerous proof-of-principal studies have shown that the
severity of concomitant disease in mice (e.g., colitis, airway
hyper-reactivity, and experimental allergic encephalitis) can
be reduced by prophylactic or therapeutic infection with
parasitic helminths [2]. The mechanism of the reduction in
disease has been, in a species- and model-speciﬁc manner,
ascribed to the inhibition of Th1 cytokine production [37],
induction of regulatory cytokines (e.g., IL-10 and TGFβ)
[38, 39], production of Foxp3+ regulatory T cells [40],
and activity of alternatively activated macrophages [41].
(A smaller number of reports have presented the caveat
that infection with helminth parasites can exaggerate other
disease conditions [42] . )T od a t ew ea r ea w a r eo fo n l yﬁ v e
publications that have assessed the eﬀect of infection with
helminth parasites on joint inﬂammation.
To our knowledge, the ﬁrst report on reduced arthritic
disease in helminth-infected rodents was the serendipitous
observation that rats infected with the nematode Syphacia
obvelata had less CFA-induced arthritis (as gauged by the
number of joints involved and degree of swelling) [43].
The identiﬁcation of the helminth was made following the
observation that some of the CFA-treated rats had limited
disease—that is, the investigators had not purposefully
infected a cohort of animals; rather the infection was
unintended.
Spontaneous arthritis develops in Murphy Roths Large
(MRL)/lpr mice. Infection of these mice with either of the
nematodes Heligmosomoides polygyrus or Nippostrongylus
brasiliensis resultedin aslightlyreducedincidenceofarthritis
and a reduction in synovial hyperplasia. Other signiﬁcant
features of arthritic disease, including pannus formation,
cartilage erosion, and bone destruction, were not attenuated
by infection with either helminth [44]. While attesting to the
potential of infection with helminth parasites to reduce the
severity of arthritic disease, this study revealed no speciﬁc
anti-inﬂammatory mechanism of action.
Recently, Osada and colleagues demonstrated that infec-
tion with the trematode Schistosoma mansoni attenuated Col
II-induced arthritis in mice [45]. In that study, na¨ ıve mice
or those infected two weeks previously with S. mansoni were
immunized with heterologous Col II. The infected animals
developed less severe arthritis, as indicated by reduced limb
involvement and swelling. While typical arthritic features
such as synovial hyperplasia, inﬂammatory cell recruitment,
and bone/cartilage destruction were present in uninfected
Col II immunized mice, mice infected with S. mansoni
were protected from arthritis as assessed by these measures
[45]. Dose studies indicated that 4-5 pairs of S. mansoniJournal of Parasitology Research 5
were suﬃcient to provide an antiarthritic eﬀect. By 8 and
12 weeks after immunization the levels of IgG2a,w h i c h
are involved in the pathology of Col II-induced arthritis,
were signiﬁcantly lowered in S. mansoni-infected mice.
Polyclonal stimulated splenic T cells from Col II-injected
mice produced substantial amounts of IFNγ,I L - 1 7 A ,a n d
TNFα, and comparatively little IL-4 and IL-10. The reverse
is true of T cells retrieved from Col II+S. mansoni-treated
mice. In addition, quantitative PCR revealed upregulation of
IL-1β and IL-6, and receptor activator of nuclear factor κ-
B ligand (RANKL) in the paws of Col II arthritic mice that
was not observed in the S. mansoni-infected mice. Analysis
of IL-10 and TGFβ mRNA revealed no diﬀerences between
the groups, and somewhat, counterintuitively, there was a
subtle increase in Foxp3 mRNA in paws from immunized
mice that was not observed in Col II+S. mansoni-treated
mice. Collectively, these data demonstrate the capacity of
a prophylactic infection with S. mansoni to attenuate the
severity of collagen-induced arthritic disease, which may be
due to systemic suppression of proinﬂammatory cytokine
production and enhanced synthesis of IL-10. Very similar
results have been reported by He et al. [46], who showed
inhibition of Col II-induced arthritis in mice infected seven
weeks, but not two weeks, previously with Schistosoma
japonicum.
Most recently it was found that infection with the rat
tapeworm, Hymenolepis diminuta signiﬁcantly attenuated
CFA-induced arthritis [23]. In this model, CFA was injected
directly into the knee of na¨ ıve Balb/c or C57/Bl6 mice. A
subset of animals was infected 8 days previously with H.
diminuta, a time-point at which immunological expulsion
of the helminth is underway. CFA-treated mice displayed
an increase in knee diameter of 20–40%, increased synovial
blood ﬂow, increased myeloperoxidase (MPO) activity (a
measure of granulocyte inﬁltrate, typically neutrophils), and
increased pain sensitivity; all of these signs and symptoms
of joint inﬂammation were reduced in the parasitized mice
[23]. Moreover, infection with H. diminuta was as eﬀective
as treatment with either the steroid dexamethasone or the
NSAIDindomethacin,atinhibiting theproarthritic eﬀectsof
intra-articular injectionofCFA.Inaddition,the antiarthritic
eﬀect of infection with H. diminuta was absent in mice
lacking T and B cells or the α-chain of the IL-4 receptor,
suggesting that the active adaptive immune response against
the parasite had the bystander eﬀect of antagonising the
eﬀects of CFA. Typical of the response to infection with
helminth parasites, spleen cells from the infected mice
produced signiﬁcantly more IL-4 and IL-10 when challenged
with the T cell-mitogen, concanavalin A, than splenocytes
from CFA-only-treated or na¨ ıve mice [23].
A subsequent series of mechanistic studies employed (i)
an in vivo neutralizing antibody against IL-10 and (ii) IL-
10 KO mice and (iii) adoptive transfer of CD4+ T cells from
H. diminuta-infected wild-type or IL-10 KO mice [23]. The
outcome of these investigations supports the conclusions
that the IL-10 component of the response to infection
with H. diminuta is important for the inhibition of CFA-
induced joint inﬂammation and that CD4+ T cells (which
could be a source of IL-10) from infected mice can transfer
protection against the proarthritic eﬀects of CFA injection
[23].
5.The ChallengesAhead
The concept of “helminth therapy” has generated signiﬁcant
interest among scientists, the public, and some patients for
whom standard therapies have either limited eﬀectiveness
or have failed [47, 48]. While the study of helminth
parasites in models of arthritis has lagged behind those of
other diseases (e.g., IBD [49]), data from murine model
systems indicate that infection with helminth parasites can
alleviate the severity of joint inﬂammation. Further, studies
in other models of arthritis are warranted. These should
be complemented with clinical data and observations and
ultimately carefully controlled double-blind clinical trails.
At this juncture, beyond the suggestion of the value of
small open-label studies with a deﬁned helminth in a well-
characterized group of patients with arthritis, it is, in our
view, premature to advocate helminth therapy for joint
inﬂammation. A major challenge in the ﬁeld will be the
identiﬁcationandcharacterizationofspeciﬁcantigensfroma
given helminth that drives the protective response and those
antigens/molecules that can serve as blueprints for drug
design in the development of novel anti-inﬂammatories or
analgesics for the treatment of an array of human maladies.
There are potential drawbacks to helminth therapy
that need to be carefully assessed: (i) certain parasites
(e.g., S. mansoni) are not viable candidates because of the
disease they cause (this does not diminish their value in
animal models for the elucidation of anti-inﬂammatory
mechanisms and immunological principles), (ii) the spectre
of iatrogenic infection, and (iii) the possibility that infection
with speciﬁc parasites could be additive to an existing
condition or promote the clinical manifestation of a disease
or comorbidities. For instance, recent data suggest that
helminth therapy could be contraindicated in treating a
disease characterized by increased numbers of eosinophils
[50]. Moreover, despite the many reports of infection with
helminth parasites blocking disease in animal models, the
exact mechanism of action is not well deﬁned, and potential
side eﬀects [51], dosing regimens, the impact of other
helminth or protozoan infections, and the immunological
and nutritional status of the host are important issues that
remain unexplored.
Assessments of the anti-inﬂammatory eﬀect(s) of infec-
tion with helminth parasites have focused on immune
factors: anobviousandimportant starting point[1,2].How-
ever, lipid-derived molecules, stromal (e.g., ﬁbroblasts) and
endocrine cells, and modulation of the normal microﬂora of
the gut all have the potential to dampen disease propagating
events. The role of these factors in helminth inhibition of
concomitant inﬂammatory disease is unknown and should
be the focus of future research endeavours.
6.Conclusions
While a few studies have shown that infection with helminth
parasites canexaggerateexistingdisease,theconsensusisthat6 Journal of Parasitology Research
the generation of an immunoregulatory environment as a
consequenceofinfection withparasitic helminths canreduce
the severity of concomitant disease (an arrangement that
would beneﬁt parasites while they complete their lifecycle).
The consideration of the impact of infection with helminth
parasites on arthritic disease is limited, but the available
data support the general concept of “helminth therapy”—
or rather, that data obtained from models of arthritis and
concomitant helminth infection have the potential to reveal
novel approaches to treat arthritis. While a number of obvi-
ous caveats pertain to helminth therapy, there is no doubt
that there is much to be learned from analyses of rodent-
helminth model systems, and a “tolerant” view of “our
wormy friends” may be warranted. This is an exciting area of
translational research thatwill eventuallygeneratenovel data
on anti-inﬂammatory, proresolution, or immunoregulatory
mediators, cells and pathways that can be converted into
new approaches to autoinﬂammatory and idiopathic human
diseases. The notion of being able to prescribe a speciﬁc
parasitic helminth to treat a disease in an individual whose
immunological status has been carefully characterized could
be a tantalizing aspect of future “personalised medicine.”
However, we see this as a future possibility and not a future
certainty and caution individuals to resist any temptation to
infect themselves with a helminth parasite. Finally, we would
emphasize that animal models need to be more rigorously
employed to comprehensively deﬁne all immuneregulatory
ramiﬁcations and potential side eﬀects of infection with
parasitic helminths in the context of other disease.
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